Category: Accuray Inc.
The prolonged slump in the U.S. defibrillator market appears to have stabilized, according to medical device company Medtronic.
Medtronic (NYSE:MDT) said the slump that's hit its bread-and-butter cardiac rhythm management division where it hurts appears to have stabilized, despite the 5% sales slide during its fiscal 1st quarter.
The best way to beat Intuitive Surgical out of the corner it has on the prostate cancer treatment market is by amping up the aggression, radiosurgery veteran and Varian chief medical officer John Adler tells MassDevice.com.
Radiosurgery innovator and medtech veteran John Adler is ready for a fight.
The outspoken inventor of Accuray's (NSDQ:ARAY) CyberKnife system, as well as the company's founder and former CEO, Adler is an evangelist for radiosurgery and its potential in a variety of applications.
Prostate surgery with robotic assistance may cause less impotence and incontinence than laparoscopic surgery, according to a small Italian study.
Robot assisted prostate surgery may lower rates of urinary incontinence and post-surgery impotence when compared with minimally invasive laparoscopy, according to a small Italian study.
The study only comprised 120 patients who were randomized to receive a prostatectomy with either an unnamed robot assistant or with tiny tools manipulated by hand. All surgeries were performed by a single surgeon.
In this 2009 video from the American Society of Radiation Oncology annual meeting, employees from Sunnyvale, Calif.-based Accuray (NSDQ:ARAY) show off their dance moves.
Radiosurgery devices company Accuray acquires medical imaging software systems maker Morphormics in a deal worth about $5.7 million.
Accuray (NSDQ:ARAY) signed a definitive agreement to acquire medical imaging software systems maker Morphormics for $5.7 million, the company announced today.
Privately held Morphormics, founded by faculty of the University of North Carolina at Chapel Hill, develops software that recognizes and extracts anatomical structures from medical images.
A new survey of U.S. hip and knee surgeons adds to Wall Street analysts' confidence that the orthopedics market is looking up.
Wall Street analysts are predicting with increasing confidence that the U.S. orthopedics market is on the upswing following an industry survey suggesting a coming increase in procedure volumes.
A MEDACorp orthopedics survey of 65 U.S. hip and knee surgeons found improvements in 12-month procedure volume expectations and increased patient willingness for surgery, according to an investment note from Leerink Swann analyst Richard Newitter.
Abiomed says it hasn't heard of any Medicare reimbursement concerns, but a note from a Wall Street analyst sends shares down 6%.; also, Accuray teams up with the German Cancer Research Center; AngioDynamics closes the $335M Navilyst merger; athenahealth may be eyeing Epocrates; Covidien launches offering to pay off senior notes; plus, a Funding Roundup and analysts' ups and downs.
Abiomed (NSDQ:ABMD) slid 6% in late afternoon trading following a note from a Wall Street analyst warning about Medicare reimbursement concerns for the company's star Impella heart pumps.